- Trial Phase
- Phase 3
- Time to Market
- Assuming positive Phase 3 data (Q3 2027), a US regulatory filing would follow around end-2027, with potential approval in 2028-2029.
- Why 4/10
- The next hard catalyst is the Phase 3 ALPHA-ORBIT topline readout (6- and 12-month efficacy data), expected in Q3 2027 — approximately 12-15 months out, beyond the 12-month window for high-impact scoring. Navenibart is a meaningful pipeline asset but BioCryst already has an approved, revenue-generating HAE drug (ORLADEYO, ~$635M+ total 2026 revenue), so this is not a single-asset binary.
Navenibart is a promising long-term pipeline story within BioCryst, but there is no imminent binary catalyst for ~12+ months. Investors should watch for interim data updates at medical conferences and the pivotal Phase 3 ALPHA-ORBIT readout in Q3 2027. In the meantime, near-term BCRX value is driven by ORLADEYO commercial execution and the ongoing business restructuring.
Price Chart
Executive Summary
Navenibart (formerly STAR-0215) is BioCryst's late-stage pipeline candidate for hereditary angioedema (HAE) prophylaxis, acquired via the $700M Astria Therapeutics deal closed January 2026. It is a long-acting monoclonal antibody that blocks plasma kallikrein and could offer best-in-class dosing convenience — every 3 or 6 months via subcutaneous injection. Phase 1b/2 ALPHA-STAR data showed reduced attack frequency and severity with a favorable safety profile. The Phase 3 ALPHA-ORBIT pivotal trial enrolled its last patient in June 2026, with topline data expected Q3 2027. BioCryst already commercializes ORLADEYO (an oral daily HAE drug generating ~$625-645M in 2026 revenue), providing an existing HAE commercial infrastructure and non-dilutive capital from a European licensing deal ($70M upfront, up to $275M milestones). However, the HAE prophylaxis market is increasingly crowded (Takeda's Takhzyro, Ionis' newly approved Dawnzera/donidalorsen, CSL's Haegarda), and navenibart faces a long wait for its pivotal readout.
How It Works
Navenibart is a lab-engineered antibody (monoclonal antibody) that blocks a protein called plasma kallikrein, which is overactive in people with hereditary angioedema (HAE) and causes sudden, painful swelling attacks. It is designed to be injected under the skin and lasts a long time in the body, potentially requiring a shot only once every 3 to 6 months — far less frequent than most current HAE preventatives.
Trial Status
Phase 1b/2 ALPHA-STAR trial completed with positive final results (Nov 2025). Phase 2 open-label extension ALPHA-SOLAR ongoing with positive interim data (June 2025). Phase 3 pivotal ALPHA-ORBIT trial enrollment completed June 2026; topline 6- and 12-month efficacy data expected Q3 2027.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 ALPHA-ORBIT topline data (Q3 2027) — 6- and 12-month efficacy readout on up to ~145 patients
- Potential interim data updates at medical conferences (EAACI, ACAAI, AAAAI)
- BCX17725 (Netherton syndrome program) proof-of-concept data expected by end of 2026 — a separate pipeline catalyst that could influence sentiment around BioCryst's external innovation strategy
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BIOCRYST PHARMACEUTICALS INC 8-K BCRX ·Originating report